Publications by authors named "E Quattrocchi"
Article Synopsis
- Burosumab is approved to treat hypophosphatemia caused by persistent tumor-induced osteomalacia, utilizing a data-informed drug development method to assess its pharmacokinetics and dosing for both adults and children.
- The study combined data from both tumor-induced osteomalacia and X-linked hypophosphatemia to refine understanding of drug behavior, using simulations to propose effective dosing recommendations that can achieve normal phosphate levels with minimal risk of hyperphosphatemia.
- Findings suggest dosing for pediatric patients at 0.3 and 0.4 mg/kg every two weeks, and for adults at 0.3 and 0.5 mg/kg every four weeks, can lead
X-linked hypophosphatemia (XLH) is a rare genetic disorder caused by excessive fibroblast growth factor 23 (FGF23), leading to low serum phosphate levels resulting in increased risk of fractures and pseudofractures. Burosumab is indicated for the treatment of XLH. In this work, we aimed to understand the quantitative relationship between burosumab-treatment-induced improvements in serum phosphate and reduction in fracture and pseudofracture counts in adults with XLH.
View Article and Find Full Text PDFBurosumab is indicated for treatment of a rare bone disease, X-linked hypophosphatemia (XLH). The aim of this analysis was to evaluate the relationship between a treatment response biomarker and patient-reported outcomes (PROs). Longitudinal data for PROs were obtained from adults with XLH from a phase III study.
View Article and Find Full Text PDFCP-GEP (Merlin) gene expression profiling: can my melanoma patient forgo sentinel lymph node biopsy?
Ital J Dermatol Venerol
August 2023
Melanoma risk stratification is crucial for both patients and physicians. Patients want to understand what to expect after diagnosis, and physicians need to decide on an appropriate treatment plan. Traditionally, risk stratification has been based on Breslow thickness and sentinel lymph node (SLN) status.
View Article and Find Full Text PDFMigraine headaches are widespread, debilitating and considered a main cause of disability worldwide. Symptoms of migraines include unilateral, pulsating pain that can last for hours to days, frequently associated with photophobia and phonophobia, nausea, or vomiting, and often aggravated by physical activity. The Canadian Headache Society and American Headache Society guidelines suggest strong evidence of the efficacy of triptans, acetaminophen, aspirin, diclofenac sodium, naproxen and ibuprofen for the acute treatment of migraines.
View Article and Find Full Text PDF